β-Muricholic acid
Based on 1 publication(s) in Google Scholar
β-Muricholic acid is a potent and orally active biliary cholesterol-desaturating agent. β-Muricholic acid prevents cholesterol gallstones. β-Muricholic acid inhibits lipid accumulation. β-Muricholic acid has the potential for the research of nonalcoholic fatty liver disease (NAFLD).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.92%
- CAS 番号: 2393-59-1
- 分子式: C24H40O5
- 分子量:408.57
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-115433
α-Muricholic acid
-
HY-121238
Hyocholic acid
-
HY-N0324
Cholic acid
-
HY-N0593
Deoxycholic acid
-
HY-122141
Glycohyocholic acid
-
HY-76847
Chenodeoxycholic Acid
-
HY-N0169
Hyodeoxycholic acid
-
HY-113212
Ursocholic acid
-
HY-135103
Tauro-β-muricholic acid sodium
-
HY-13771
Ursodeoxycholic acid
-
HY-113238A
Lithocholic acid 3-sulfate disodium
-
HY-N2334
Glycochenodeoxycholic acid
MedChemExpress（MCE）の使用を引用している文献 β-Muricholic acid
More
Customer Validation & Images
-
2D/3D Cell Culture and Differentiation
-
RT-PCR
-
IF
Endogenous Metabolite アイソフォーム固有の製品をすべて表示
More
生物活性
β-Muricholic acid (100 µM; 48 h) inhibits lipid accumulation in mouse primary hepatocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6-8 weeks, Male C57L/J mice (with a lithogenic diet (2% cholesterol and 0.5% cholic acid))[2]
-
Dosage:0.5% β-muricholic acid
-
Administration:Fed chow with 0.5% β-muricholic acid for 8 weeks
-
Result:Decreased gallstone prevalence to 20% through significantly reducing biliary secretion rate, saturation index, and intestinal absorption of cholesterol, as well as inducing phase boundary shift and an enlarged Region E that prevented the transition of cholesterol from its liquid crystalline phase to solid crystals and stones.
化学情報
-
CAS 番号 2393-59-1
-
性状 Solid
-
分子量 408.57
-
分子式 C24H40O5
-
Color White to light yellow
-
SMILES
C[C@H](CCC(O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)[C@@H](O)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Commun Biol
Lactobacillus rhamnosus GG maintains gut microbiota stability and promotes intestinal adaptation via activated intestinal farnesoid X receptor signaling in short bowel syndrome. [Abstract]2025 May 27;8(1):816. PMID: 40425822
β-Muricholic acid purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 May 27;8(1):816. [Abstract]
Morphological changes of mouse ileum organoids treated with LGGs (2%, 4%, or 8%) or β-MCA (β-Muricholic acid; 0.1-0.8 mM; 24 h). β-MCA at 0.8 mM induced epithelial damage.
β-Muricholic acid purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 May 27;8(1):816. [Abstract]
Suppression of FXR signaling pathway mRNA levels in mouse ileum organoids treated with β-MCA (β-Muricholic acid; 0.4 mM; 24 h). FXR, OST-α, OST-β, and I-BABP expression decreased.
β-Muricholic acid purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 May 27;8(1):816. [Abstract]
Immunofluorescence staining of FXR (red) and ASBT (green) in mouse ileum organoids treated with LGGs (2%), β-MCA (β-Muricholic acid; 0.4 mM; 24 h), or their combination, with nuclei counterstained with DAPI (blue). β-MCA reduced FXR protein expression and increased ASBT protein expression.
溶剤 & 溶解度
DMSO : 100 mg/mL (244.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.12 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.12 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Takada S, et al. Stress can attenuate hepatic lipid accumulation via elevation of hepatic β-muricholic acid levels in mice with nonalcoholic steatohepatitis. Lab Invest. 2021 Feb;101(2):193-203. [Content Brief]
[2]. Wang DQ, et al. Effect of beta-muricholic acid on the prevention and dissolution of cholesterol gallstones in C57L/J mice. J Lipid Res. 2002 Nov;43(11):1960-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4476 mL | 12.2378 mL | 24.4756 mL | 61.1890 mL |
| 5 mM | 0.4895 mL | 2.4476 mL | 4.8951 mL | 12.2378 mL | |
| 10 mM | 0.2448 mL | 1.2238 mL | 2.4476 mL | 6.1189 mL | |
| 15 mM | 0.1632 mL | 0.8159 mL | 1.6317 mL | 4.0793 mL | |
| 20 mM | 0.1224 mL | 0.6119 mL | 1.2238 mL | 3.0595 mL | |
| 25 mM | 0.0979 mL | 0.4895 mL | 0.9790 mL | 2.4476 mL | |
| 30 mM | 0.0816 mL | 0.4079 mL | 0.8159 mL | 2.0396 mL | |
| 40 mM | 0.0612 mL | 0.3059 mL | 0.6119 mL | 1.5297 mL | |
| 50 mM | 0.0490 mL | 0.2448 mL | 0.4895 mL | 1.2238 mL | |
| 60 mM | 0.0408 mL | 0.2040 mL | 0.4079 mL | 1.0198 mL | |
| 80 mM | 0.0306 mL | 0.1530 mL | 0.3059 mL | 0.7649 mL | |
| 100 mM | 0.0245 mL | 0.1224 mL | 0.2448 mL | 0.6119 mL |
β-Muricholic acid 関連分類
HY-133707 関連分類
Powered by Bioz